After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
16 September 2024
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
30 August 2024
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
29 August 2024
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
28 August 2024
It’s back to school for biotech, with a packed conference schedule.
28 August 2024
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
27 August 2024
Bicara and DualityBio will soon test market appetite for new oncology issues.
27 August 2024
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
Recent Quick take
- 23 July 2024
- 22 July 2024
- 17 July 2024
- 17 July 2024
- 17 July 2024
- 15 July 2024
- 12 July 2024
- 12 July 2024
- 11 July 2024